ongoing chronic treatment
North America 8.1.1
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL
This study demonstrated that -LA supplementation (300 mg/d, twice a day) for 3 months significantly decreased the serum levels of MDA and C-reactive protein (CRP), as two inflammatory and oxidative stress markers, and mood disorders in patients with episodic migraine
Beyond safety, understanding how tirzepatide works in the real world, in diverse groups of people, including those with multiple health conditions or limited access to medical care, is crucial